Skip to content
DataLookout
Menu

NCT06872892

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 46 versions: 46 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites reduced: 478 → 474 locations
  2. Minor Study sites revised (478)
  3. Minor Study sites revised (478)
    • Publications expanded, about 63 words
  4. Minor Trial sites expanded: 471 → 478 locations
  5. Notable Eligibility criteria expanded, about 20 words
    • Study sites: 470 to 471
    • Secondary endpoints: details revised at 1 of 6 entries
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites: 471 to 470v41
  2. Minor Study sites: 470 to 471v40
  1. Notable Primary completion moved earlier from Sep 14, 2028 to Jun 15, 2027
    • Study completion moved earlier from Oct 12, 2028 to Dec 20, 2027
    • Study sites revised (470)
    v39
  2. Minor Trial sites reduced: 488 → 470 locationsv38
  3. Minor Trial sites reduced: 494 → 488 locationsv37
  4. Minor Study sites revised (494)v36
  5. Minor Study sites revised (494)v35
  6. Notable Eligibility criteria revised
    • Site details revised at 9 of 494 sites
    v34
  7. Minor Site details revised at 27 of 494 sitesv33
  8. Minor Study sites: 495 to 494v32
  9. Minor Trial sites reduced: 498 → 495 locationsv31
  10. Minor Study sites: 497 to 498v30
  11. Minor Study sites revised (497)v29
  12. Minor Study sites: 498 to 497v28
  13. Minor Study sites: 499 to 498v27
  14. Minor Study sites: 503 to 499v26
  15. Minor Study sites: 501 to 503v25
  16. Minor Study sites: 505 to 501v24
  17. Minor Study sites: 511 to 505v23
  18. Minor Study sites: 508 to 511v22
  19. Minor Study sites: 512 to 508v21
  20. Notable Primary completion date: Jul 5, 2027 to Sep 14, 2028
    • Study completion date: Aug 2, 2027 to Oct 12, 2028
    v20
  21. Notable Primary completion date: Sep 14, 2028 to Jul 5, 2027
    • Study sites: 511 to 512
    • Study completion date: Oct 12, 2028 to Aug 2, 2027
    v19
  22. Minor Study sites: 513 to 511v18
  23. Notable Eligibility criteria expanded, about 34 wordsv17 Show 4 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 1680 to 1755
    • Secondary endpoints revised (6)
    • Study title revised
  24. Minor Study sites: 511 to 513v16
  25. Minor Study sites revised (511)v15
  26. Minor Study sites: 503 to 511v14
  27. Minor Study sites: 485 to 503v13
  28. Minor Study sites: 477 to 485v12
  29. Minor Study sites revised (477)v11
  30. Minor Study sites: 462 to 477v10
  31. Minor Study sites: 441 to 462v9
  32. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 414 to 441
    • Start date changed from estimate of Jun 16, 2025 to Jun 9, 2025
    v8
  33. Minor Study sites: 394 to 414v7
  34. Minor Study sites: 384 to 394v6
  35. Minor Study sites: 375 to 384v5
  36. Minor Study sites: 321 to 375v4
  37. Minor Study sites: 301 to 321v3
  38. Minor Study sites: 0 to 301v2
  39. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Annualised rate of adjudicated pulmonary exacerbations (number of events per person year) up to Week 76
Timeframe: up to 76 weeks

Secondary (6)

Time to first adjudicated pulmonary exacerbation up to Week 76
Absolute change from baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) respiratory symptoms domain score at Week 52 (participants ≥ 16 years)
Absolute change from baseline in post-bronchodilator Forced Expiratory Volume in the first second (FEV1) %pred at Week 52
Absolute change from baseline in post-bronchodilator Forced Vital Capacity (FVC) %pred at Week 52
Annualised rate of severe adjudicated pulmonary exacerbations up to Week 76
Show 1 moreShow less
Time to first adjudicated severe pulmonary exacerbation up to Week 76

Arms and interventions

Treatment armExperimental
Placebo armPlacebo comparator

Drugs: BI 1291583, Placebo matching BI 1291583

Sites

474 sites in 46 countries

United States 75, China 51, Japan 38, Germany 33, United Kingdom 23, Spain 21, South Korea 18, Italy 16, Australia 15, Argentina 12, France 11, Canada 10, Bulgaria 9, India 8, Mexico 8, Brazil 7, Latvia 7, New Zealand 7, Portugal 7, Malaysia 6, Netherlands 6, Poland 6, Taiwan 6, Denmark 5, Israel 5, Philippines 5, South Africa 5, Thailand 5, Belgium 4, Finland 4, Romania 4, Singapore 4, Czechia 3, Hungary 3, Ireland 3, Lithuania 3, Puerto Rico 3, Sweden 3, Austria 2, Chile 2, Croatia 2, Hong Kong 2, Kazakhstan 2, Slovakia 2, Switzerland 2, Turkey (Türkiye) 1